Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

(03) 9028 2888

clients@freshequities.com

Immuron Limited

INVESTOR PRESENTATION - Immuron Limited

ASX:IMC

Immuron Limited

Health

Immuron Ltd is an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in pathogenesis. These disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile.

Read more

Market Cap

$52.17m

Price at Close

$0.23

4w avg. Volume

228.78k

4w avg. Turnover

$51.86k

Announcements
announcementt+2 movementdate
  • Investor Presentation

    Periodic Reports

  • -2.22%

    10 Jan 2021

-2.22%

10 Jan 2021
  • Immuron to Participate in BioConnect 2021 Virtual Conference

    Company Administration

  • -2.22%

    10 Jan 2021

-2.22%

10 Jan 2021
  • Immuron SARS-CoV-2 Research Agreement with Monash University

    Progress Report · Market sensitive

  • +2.08%

    14 Dec 2020

+2.08%

14 Dec 2020
  • Change of Director's Interest Notice (DP)

    Shareholder Details

  • -1.96%

    25 Nov 2020

-1.96%

25 Nov 2020
  • Immuron Receives AUD $358,280 R&D Tax Concession Refund

    Periodic Reports · Market sensitive

  • -1.92%

    23 Nov 2020

-1.92%

23 Nov 2020
  • 708A Notice

    Issued Capital

  • +4.00%

    18 Nov 2020

+4.00%

18 Nov 2020
  • Appendix 3G

    Issued Capital

  • +6.00%

    17 Nov 2020

+6.00%

17 Nov 2020
  • Change of Director's Interest Notice (x5)

    Shareholder Details

  • +6.00%

    17 Nov 2020

+6.00%

17 Nov 2020
  • Change in substantial holding

    Shareholder Details

  • 0.00%

    15 Nov 2020

0.00%

15 Nov 2020
  • Appendix 2A

    Issued Capital

  • -1.96%

    13 Nov 2020

-1.96%

13 Nov 2020
Market Data

Current Price

$0.23

52WK HIGH

$0.95

52WK LOW

$0.05

1YR RETURN

+70.37%

1YR RETURN VS. SECTOR

+32.86%

90 DAY RETURN

-13.21%

ASX RANK

1,150

/2,047

SECTOR RANK

101

/168

SHARES OUTSTANDING

226.84m
ASX:IMC

Immuron Limited

Health

Immuron Ltd is an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in pathogenesis. These disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile.

Read more

Market Cap

$52.17m

Price at Close

$0.23

4w avg. Volume

228.78k

4w avg. Turnover

$51.86k

ASX:IMC is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.